Endothelin receptor antagonist reduces markers of PCa

Chicago-The selective endothelin receptor antagonist atrasentan significantly attenuates changes in biochemical markers of bone metabolism and disease progression in a group of patients with advanced hormone-refractory prostate cancer that had progressed on placebo, according to the results of a randomized clinical trial.

Related Videos

Related Content

Advertisement

December 16th 2024

Efficacy of sildenafil cream for FSAD maintained across patient subgroups

Hannah Clarke

Age, race, and hormonal contraceptive use did not significantly impact the efficacy of sildenafil cream, 3.6%, in female sexual arousal disorder.

July 24th 2024

Speaking of Urology: Dr. Winter on the use of vaginal estrogen

Urology Times staff

In this episode of Speaking of Urology®, Ashley G. Winter, MD, discusses the use of vaginal estrogen.

September 10th 2024

Data show short-term benefit of certain hormonal treatments for GSM

Hannah Clarke

Data showed that vaginal estrogen, vaginal DHEA, oral ospemifene, and vaginal moisturizers may provide benefit in the management of symptoms related to GSM.

March 17th 2022

Dr. Malik evaluates quality of Reddit content on recurrent UTIs

Urology Times staff

“I think we as urologists have to be proactive in providing information to our patients so that they avoid financial harm and potentially bodily harm from this sort of misinformation,” says Rena D. Malik, MD.

August 27th 2024

Topical sildenafil cream found safe, tolerable in female sexual arousal disorder

Hannah Clarke

There were no differences in the number of treatment-related TEAEs in patients who received sildenafil cream vs patients who received placebo.

March 25th 2024

National Urogynecology Research Agenda: A Path Forward for Advancing the Treatment and Management of Pelvic Floor Disorders

American Urogynecologic Society

Developed by the AUGS Scientific Committee and Research Agenda Writing Group

Related Content

Advertisement

December 16th 2024

Efficacy of sildenafil cream for FSAD maintained across patient subgroups

Hannah Clarke

Age, race, and hormonal contraceptive use did not significantly impact the efficacy of sildenafil cream, 3.6%, in female sexual arousal disorder.

July 24th 2024

Speaking of Urology: Dr. Winter on the use of vaginal estrogen

Urology Times staff

In this episode of Speaking of Urology®, Ashley G. Winter, MD, discusses the use of vaginal estrogen.

September 10th 2024

Data show short-term benefit of certain hormonal treatments for GSM

Hannah Clarke

Data showed that vaginal estrogen, vaginal DHEA, oral ospemifene, and vaginal moisturizers may provide benefit in the management of symptoms related to GSM.

March 17th 2022

Dr. Malik evaluates quality of Reddit content on recurrent UTIs

Urology Times staff

“I think we as urologists have to be proactive in providing information to our patients so that they avoid financial harm and potentially bodily harm from this sort of misinformation,” says Rena D. Malik, MD.

August 27th 2024

Topical sildenafil cream found safe, tolerable in female sexual arousal disorder

Hannah Clarke

There were no differences in the number of treatment-related TEAEs in patients who received sildenafil cream vs patients who received placebo.

March 25th 2024

National Urogynecology Research Agenda: A Path Forward for Advancing the Treatment and Management of Pelvic Floor Disorders

American Urogynecologic Society

Developed by the AUGS Scientific Committee and Research Agenda Writing Group